Candy giant Mars partners with biotech firm to gene-edit cocoa supply

Candy giant Mars partners with biotech firm to gene-edit cocoa supply


Packages of M&M’s milk chocolate candy are stacked at a Costco Wholesale store on July 12, 2025 in San Diego, California.

Kevin Carter | Getty Images News | Getty Images

Candy maker Mars said Wednesday it’s partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology.

The agreement gives the M&M’s maker access to Pairwise’s Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable.

CRISPR is a gene editing tool that makes fast and precise changes to DNA. In farming, it’s used to improve crops by targeting different traits like drought and disease resistance.

The goal is to create cacao plants — the source of cacao beans, which are then roasted and made into cocoa — that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.

In October, Starbucks invested in two innovation farms in Central America to protect the chain’s coffee supply from global warming. The farms develop climate-resilient coffee and test technologies like drones and mechanization.

Gene editing allows for faster and more precise trait development than traditional breeding, Pairwise said in a press release.

CRISPR has garnered attention in recent years for its applications in health care. In late 2023, the U.S. Food and Drug Administration approved the first gene-editing treatment for sickle cell disease.

“At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains,” said Carl Jones, Plant Sciences Director at Mars, in the release.

Last month, the candy giant announced a $2 billion investment in U.S. manufacturing through 2026. This includes a new $240 million investment for a Nature’s Bakery facility in Utah.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More